Analgesic Efficacy of Maxigesic in Breast Cancer Surgery

Last updated: December 21, 2023
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Cancer

Cancer

Treatment

0.9% saline solution

Maxigesic

Clinical Study ID

NCT06174363
4-2022-1650
  • Ages 20-70
  • Female

Study Summary

The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancersurgery (cancer resection or reconstruction)

Exclusion

Exclusion Criteria:

  • ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renaldysfunction/ pregnancy

Study Design

Total Participants: 84
Treatment Group(s): 2
Primary Treatment: 0.9% saline solution
Phase:
Study Start date:
April 03, 2023
Estimated Completion Date:
February 26, 2025

Connect with a study center

  • Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.